- “FDA nominee Heidi Overton does not have the support of the Hill to move forward with her confirmation,” a senior administration official told Axios on Tuesday.
Zoom: Overton, a physician and deputy director of the White House Domestic Policy Council, was appointed by President Trump in August.
- She had drawn criticism from segments of the MAHA movement who saw her siding with health and agricultural interests and helping to undermine Kennedy’s agenda.
- Anti-abortion forces also questioned his commitment to strengthening prescribing rules for mifepristone, the abortion pill.
The backstory: His nomination was met with opposition from Democrats and skepticism from some Republican senators, including Sen. Bill Cassidy (R-La.), chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee.
- Cassidy said he was “strongly concerned” about Overton’s role in the administration’s efforts to change recommendations on childhood vaccines, which he called “almost disqualifying.”
What they say: “We need to take a new direction at the FDA, and everyone fully supports Secretary Kennedy’s vision to make America healthy again and return to a more populist, common-sense approach to health in America,” the senior administration official said.
- The White House had tried to shore up his nomination on Monday, posting on social media an account of the former dean of the University of New Mexico School of Medicine supporting Overton’s confirmation.
What’s next: The HELP committee was scheduled to vote Wednesday on Overton’s nomination.
- The FDA has been led by Acting Commissioner Kyle Diamantas since Marty Makary resigned in May.
Gn headline
